Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Amortization of Deferred Charges (2019 - 2021)

Usana Health Sciences (USNA) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $2.2 million as the latest value for Q4 2021.

  • On a quarterly basis, Amortization of Deferred Charges rose 5.51% to $2.2 million in Q4 2021 year-over-year; TTM through Oct 2021 was $9.1 million, a 4.78% increase, with the full-year FY2021 number at $8.8 million, up 6.03% from a year prior.
  • Amortization of Deferred Charges was $2.2 million for Q4 2021 at Usana Health Sciences, down from $2.3 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $2.3 million in Q1 2021 to a low of $2.0 million in Q2 2019.
  • A 3-year average of $2.2 million and a median of $2.2 million in 2019 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: grew 11.47% in 2020, then rose 0.18% in 2021.
  • Usana Health Sciences' Amortization of Deferred Charges stood at $2.2 million in 2019, then fell by 2.07% to $2.1 million in 2020, then grew by 5.51% to $2.2 million in 2021.
  • Per Business Quant, the three most recent readings for USNA's Amortization of Deferred Charges are $2.2 million (Q4 2021), $2.3 million (Q3 2021), and $2.3 million (Q2 2021).